Spectroscopy firm Dxcover raises £10M in series A and grant funding
'Liquid biopsy' technique aimed at early-stage cancer diagnosis via algorithmic analysis of infrared spectra.
Stay updated with breaking news from Clinspec Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
'Liquid biopsy' technique aimed at early-stage cancer diagnosis via algorithmic analysis of infrared spectra.
Dr Mark Hegarty is chief executive and co-founder of Glasgow-based medtech firm Dxcover.
ClinSpec Diagnostics reaches funding target of £3.5m 5th March 2021 Glasgow-based ClinSpec Diagnostics has secured an additional £1.1m investment, reaching its round two funding target of £3.5m. ClinSpec, a spin-out company from the University of Strathclyde’s Department of Pure and Applied Chemistry, is aiming to develop liquid biopsies for the early detection of cancer. The new £1.1m investment from the latest funding round comes from a range of investors, including Norcliffe Capital Limited, the University of Strathclyde, Eos Advisory and the founders. The first £2.4m was secured i...